GlassScriptPhysician profile
Muhammad T Qamar
NPI 1497916720
$3,704.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,475 · 2020: $24.69 · 2021: $177 · 2022: $27.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,414.52 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.63 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $52.82 | 2021 | |
| Lundbeck LLC | $49.32 | 2019 | |
| Neuronetics, INC. | $26.61 | 2019-2020 | |
| Alkermes, INC. | $23.10 | 2019 | |
| Abbvie INC. | $18.48 | 2021 | |
| Indivior INC. | $15.85 | 2021 | |
| Allergan, INC. | $14.88 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.49 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Qamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.